Systemic Inflammation is an Important Risk Factor and Predictor of Graft Loss and Mortality One Year After Kidney Transplantation

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2025 Mar 6

PMID 40046053

Authors

Torbjorn F Heldal

Anders Asberg

Thor Ueland

Anna V Reisaeter

Soren E Pischke

Tom E Mollnes

Pal Aukrust

Finn P Reinholt

Anders Hartmann

Kristian Heldal

Trond G Jenssen

Affiliations

Soon will be listed here.

Abstract

Background: An inflammatory environment following kidney transplantation is associated with increased risk of graft loss and mortality, however, evaluation of systemic inflammation is not implemented in structured risk assessment in kidney transplant recipients. Long-term results after transplantation are not satisfactory, and thus tools addressing these issues are needed. In this study, we tested the associations and predictive abilities of a predefined systemic inflammation score one year after transplantation on death-censored graft loss and mortality.

Methods: We included 805 patients who underwent kidney transplantation between 2013 and 2017 at the Oslo University Hospital, Rikshospitalet. The inflammation score included five specifically selected biomarkers known to reflect various inflammatory pathways and to be associated with adverse outcomes following transplantation. The score was assessed in relation to outcomes in models with established risk factors. Discriminatory analyses were performed using Harrell´s C-statistic, and model assessment were evaluated using internal validation, calibration, and likelihood ratio tests.

Results: The median follow-up time was 6.4 years. There were 168 deaths (20.9%) and 42 graft losses (5.2%). The inflammation score one year after transplantation was significantly associated with graft loss (P<0.001) and mortality (P<0.001). The diagnostic performance of the model for graft loss revealed a c-statistic of 0.77 both with and without histological data. The diagnostic performance for mortality displayed a c-statistic of 0.79. In all tested scenarios, the model fit significantly improved after including the inflammation score.

Conclusions: These results suggest a strong association between systemic inflammation one year after transplantation and both graft loss and mortality. Predictive models including the inflammation score and established risk factors were particularly informative when considering mortality. Evaluation of systemic inflammation using this score could be an important tool for risk-assessment after transplantation.

References

Kared H, Alirezaylavasani A, Lund K, Chopra A, Tietze L, de Matos Kasahara T . Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients. EBioMedicine. 2023; 97:104833. PMC: 10585642. DOI: 10.1016/j.ebiom.2023.104833. View

Inker L, Eneanya N, Coresh J, Tighiouart H, Wang D, Sang Y . New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021; 385(19):1737-1749. PMC: 8822996. DOI: 10.1056/NEJMoa2102953. View

Collins G, Moons K, Dhiman P, Riley R, Beam A, Van Calster B . TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024; 385:e078378. PMC: 11019967. DOI: 10.1136/bmj-2023-078378. View

Naesens M, Schneeberger S . Redefining Risk Stratification and Endpoints for Clinical Trials in Kidney Transplantation: Rationale and Methodology of Proposals Submitted to the European Medicines Agency by the European Society for Organ Transplantation. Transpl Int. 2022; 35:10142. PMC: 9386734. DOI: 10.3389/ti.2021.10142. View

Aubert O, Divard G, Pascual J, Oppenheimer F, Sommerer C, Citterio F . Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. BMJ Open. 2021; 11(10):e052138. PMC: 8499283. DOI: 10.1136/bmjopen-2021-052138. View

Van Calster B, Wynants L, Verbeek J, Verbakel J, Christodoulou E, Vickers A . Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. Eur Urol. 2018; 74(6):796-804. PMC: 6261531. DOI: 10.1016/j.eururo.2018.08.038. View

Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M . The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2020; 20(9):2318-2331. PMC: 7496245. DOI: 10.1111/ajt.15898. View

Callemeyn J, Lamarthee B, Koenig A, Koshy P, Thaunat O, Naesens M . Allorecognition and the spectrum of kidney transplant rejection. Kidney Int. 2021; 101(4):692-710. DOI: 10.1016/j.kint.2021.11.029. View

Bergseth G, Ludviksen J, Kirschfink M, Giclas P, Nilsson B, Mollnes T . An international serum standard for application in assays to detect human complement activation products. Mol Immunol. 2013; 56(3):232-9. DOI: 10.1016/j.molimm.2013.05.221. View

10.

Abedini S, Holme I, Marz W, Weihrauch G, Fellstrom B, Jardine A . Inflammation in renal transplantation. Clin J Am Soc Nephrol. 2009; 4(7):1246-54. PMC: 2709521. DOI: 10.2215/CJN.00930209. View

11.

Helantera I, Dorje C, Ortiz F, Reisaeter A, Hammarstrom C, Lauronen J . Very Low Frequency of Pathological Findings in One-year Protocol Biopsies of Uneventful Standard Risk Kidney Transplant Recipients: Results From the Nordic Protocol Biopsy Study. Transplant Direct. 2024; 10(5):e1621. PMC: 11013703. DOI: 10.1097/TXD.0000000000001621. View

12.

Witczak B, Pischke S, Reisaeter A, Midtvedt K, Ludviksen J, Heldal K . Elevated Terminal C5b-9 Complement Complex 10 Weeks Post Kidney Transplantation Was Associated With Reduced Long-Term Patient and Kidney Graft Survival. Front Immunol. 2021; 12:738927. PMC: 8573334. DOI: 10.3389/fimmu.2021.738927. View

13.

Mollnes T, Lea T, Froland S, HARBOE M . Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol. 1985; 22(2):197-202. DOI: 10.1111/j.1365-3083.1985.tb01871.x. View

14.

Coemans M, Susal C, Dohler B, Anglicheau D, Giral M, Bestard O . Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. Kidney Int. 2018; 94(5):964-973. DOI: 10.1016/j.kint.2018.05.018. View

15.

Aubert O, Ursule-Dufait C, Brousse R, Gueguen J, Racape M, Raynaud M . Cell-free DNA for the detection of kidney allograft rejection. Nat Med. 2024; 30(8):2320-2327. PMC: 11333280. DOI: 10.1038/s41591-024-03087-3. View

16.

Bonaccio M, Di Castelnuovo A, Pounis G, De Curtis A, Costanzo S, Persichillo M . A score of low-grade inflammation and risk of mortality: prospective findings from the Moli-sani study. Haematologica. 2016; 101(11):1434-1441. PMC: 5394885. DOI: 10.3324/haematol.2016.144055. View

17.

Klein A, Kosinski L, Loupy A, Frey E, Stegall M, Helantera I . Comparing the prognostic performance of iBOX and biopsy-proven acute rejection for long-term kidney graft survival. Am J Transplant. 2024; 24(10):1784-1793. DOI: 10.1016/j.ajt.2024.04.004. View

18.

Lamarthee B, Callemeyn J, Van Herck Y, Antoranz A, Anglicheau D, Boada P . Transcriptional and spatial profiling of the kidney allograft unravels a central role for FcyRIII+ innate immune cells in rejection. Nat Commun. 2023; 14(1):4359. PMC: 10356785. DOI: 10.1038/s41467-023-39859-7. View

19.

Heldal T, Asberg A, Ueland T, Reisaeter A, Pischke S, Mollnes T . Systemic inflammation early after kidney transplantation is associated with long-term graft loss: a cohort study. Front Immunol. 2023; 14:1253991. PMC: 10577420. DOI: 10.3389/fimmu.2023.1253991. View

20.

Van Loon E, Tinel C, de Loor H, Bossuyt X, Callemeyn J, Coemans M . Automated Urinary Chemokine Assays for Noninvasive Detection of Kidney Transplant Rejection: A Prospective Cohort Study. Am J Kidney Dis. 2023; 83(4):467-476. DOI: 10.1053/j.ajkd.2023.07.022. View